Number of the records: 1
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes
- 1.
SYSNO ASEP 0558632 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes Author(s) Bigdelou, B. (US)
Sepand, M. (US)
Najafikhoshnoo, S. (US)
Negrete, J. (US)
Sharaf, M. (SA)
Ho, J. (US)
Sullivan, I. (US)
Chauhan, Prashant (BC-A) ORCID, RID
Etter, M. (CH)
Shekarian, T. (CH)
Liang, O. (US)
Hutter, G. (CH)
Esfandiarpour, R. (US)
Zanganeh, S. (US)Number of authors 14 Article number 890517 Source Title Frontiers in Immunology. - : Frontiers Media - ISSN 1664-3224
Roč. 13, MAY (2022)Number of pages 16 s. Publication form Print - P Language eng - English Country CH - Switzerland Keywords insulin-resistance ; sex-differences ; adipose-tissue ; cytokine storm ; liver-disease ; alcohol-use ; coronavirus ; infections ; obesity ; mechanisms ; coronavirus disease 2019 ; covid-19 ; immune responses ; cancer ; cardiovascular disease ; diabetes ; treatment implications Subject RIV EC - Immunology OECD category Immunology Method of publishing Open access Institutional support BC-A - RVO:60077344 UT WOS 000811304700001 EID SCOPUS 85132081170 DOI 10.3389/fimmu.2022.890517 Annotation Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host-viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities. Workplace Biology Centre (since 2006) Contact Dana Hypšová, eje@eje.cz, Tel.: 387 775 214 Year of Publishing 2023 Electronic address https://www.frontiersin.org/articles/10.3389/fimmu.2022.890517/full
Number of the records: 1